35. Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010 Sep;12(5):435-42. \[[PubMed: 20880437](https://pubmed.ncbi.nlm.nih.gov/20880437)\] 36. Kelly PA. Does recreational ecstasy use cause long-term cognitive problems? West J Med. 2000 Aug;173(2):129-30. \[[PMC free article: PMC1071023](/pmc/articles/PMC1071023/)\] \[[PubMed: 10924441](https://pubmed.ncbi.nlm.nih.gov/10924441)\] 37. Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett. 2000 Mar 15;112-113:143-6. \[[PubMed: 10720723](https://pubmed.ncbi.nlm.nih.gov/10720723)\] 38. Figurasin R, Lee VR, Maguire NJ. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 17, 2024. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. \[[PubMed: 30860717](https://pubmed.ncbi.nlm.nih.gov/30860717)\] 39. Peters GJ, Kok G. A structured review of reasons for ecstasy use and related behaviours: pointers for future research. BMC Public Health. 2009 Jul 13;9:230. \[[PMC free article: PMC2717953](/pmc/articles/PMC2717953/)\] \[[PubMed: 19594926](https://pubmed.ncbi.nlm.nih.gov/19594926)\] **Disclosure:** Rick Figurasin declares no relevant financial relationships with ineligible companies. **Disclosure:** Vincent Lee declares no relevant financial relationships with ineligible companies. **Disclosure:** Nicole Maguire declares no relevant financial relationships with ineligible companies.